Iniciar sesión

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces the same desired effect at a lower dose. It is noteworthy that both drugs exhibit similar maximum effect or Emax values, implying that they possess equal efficacy. Efficacy depends on the number of drug–receptor complexes formed and the extent of receptor activation. Maximal efficacy is achieved when all receptors are occupied, rendering further increases in drug concentration incapable of eliciting additional responses. Full agonists have high efficacy, as they activate receptors entirely and elicit a complete response. The efficacy of partial agonists is lower, as they activate receptors to a lesser extent. Antagonists, in contrast, exhibit zero efficacy by not activating the receptors. Instead, they act as blockers and either reduce the number of available receptors for agonist binding or induce conformational changes that prevent effective agonist binding. Overall, these factors play a crucial role in determining the efficacy and potency of drugs, which, in turn, can determine their usefulness in treating various medical conditions.

Tags

Dose response RelationshipPotencyEfficacyEC50 ValuesCandesartanIrbesartanMaximum EffectEmax ValuesDrug receptor ComplexesReceptor ActivationFull AgonistsPartial AgonistsAntagonistsDrug ConcentrationMedical Treatment

Del capítulo 4:

article

Now Playing

4.9 : Dose-Response Relationship: Potency and Efficacy

Pharmacodynamics

4.0K Vistas

article

4.1 : Principios de Acción de las Drogas

Pharmacodynamics

5.5K Vistas

article

4.2 : Objetivos para la acción de los medicamentos: Visión general

Pharmacodynamics

5.5K Vistas

article

4.3 : Transducción de señales: descripción general

Pharmacodynamics

8.0K Vistas

article

4.4 : Mecanismo del transductor: Receptores acoplados a proteínas G

Pharmacodynamics

1.7K Vistas

article

4.5 : Receptor de canal iónico activado por ligando: mecanismo de compuerta

Pharmacodynamics

2.0K Vistas

article

4.6 : Mecanismo del transductor: receptores ligados a enzimas

Pharmacodynamics

2.2K Vistas

article

4.7 : Mecanismo del Transductor: Receptores Nucleares

Pharmacodynamics

1.2K Vistas

article

4.8 : Relación dosis-respuesta: Introducción

Pharmacodynamics

2.8K Vistas

article

4.10 : Relación Dosis-Respuesta: Selectividad y Especificidad

Pharmacodynamics

6.1K Vistas

article

4.11 : Índice terapéutico

Pharmacodynamics

3.9K Vistas

article

4.12 : Interacción Fármaco-Receptor: Agonista

Pharmacodynamics

2.2K Vistas

article

4.13 : Interacción Fármaco-Receptor: Antagonista

Pharmacodynamics

2.5K Vistas

article

4.14 : Efectos combinados de las drogas: antagonismo

Pharmacodynamics

7.8K Vistas

article

4.15 : Efectos combinados de los medicamentos: sinergismo

Pharmacodynamics

3.3K Vistas

See More

JoVE Logo

Privacidad

Condiciones de uso

Políticas

Investigación

Educación

ACERCA DE JoVE

Copyright © 2025 MyJoVE Corporation. Todos los derechos reservados